Firebrick Pharma Limited

As of June 30, 2025, Firebrick Pharma Limited carries a market capitalization of 13.92M, placing it among publicly traded companies globally. Its enterprise value stands at 12.94M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Firebrick Pharma Limited has 224.58M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 44.43, and the price-to-book ratio stands at 8.95.

These figures are as of June 30, 2025. The EV/Sales ratio of 44.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 12.94M versus a market cap of 13.92M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2025, Firebrick Pharma Limited maintains a current ratio of 5.47, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Firebrick Pharma Limited posted a negative return on equity (ROE) of -143.50, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -124.44, reflecting losses generated across the asset base. Inventory turnover of 0.87 indicates how many times Firebrick Pharma Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Firebrick Pharma Limited's stock has declined approximately 51.61% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.05.

Over the twelve months ended June 30, 2025, Firebrick Pharma Limited generated 293,422.00 in revenue and converted that into -2.63M in net income, yielding earnings per share of -0.01. EBITDA reached -2.86M, while operating income came in at -2.87M.

These figures are as of June 30, 2025. Total book value stands at 1.56M, with working capital of 1.21M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

Over the twelve months ended June 30, 2025, Firebrick Pharma Limited posted a gross margin of 35.72, reflecting its pricing power and cost economics. The operating margin of -976.65 and net profit margin of -897.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -14.51, meaning Firebrick Pharma Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2025, Firebrick Pharma Limited has an Altman Z-Score of 12.19, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.